Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Lancet Rheumatol 2023;5:e542–52. doi: 10.1016/S2665-9913(23)00120-0
Week 16 primary outcomes of improved PASI 90 response and sPGA score demonstrated Mirikizumab superiority to placebo and non-inferiority to secukinumab. This study presented results from the OASIS-2 trial on the safety and efficacy of mirikizumab compared with secukinumab and placebo in patients with moderate-to-severe plaque psoriasis.
Analysis of the 1465 participants consisted of a 16-week induction treatment period and a 32-week maintenance treatment period. At week 0 participants were given either 250mg mirikizumab, 300mg secukinumab or placebo, followed by either 250mg or 125mg mirikizumab, or 300mg of secukinumab at week 16.
Keywords:
